Objective To investigate the effects of anlotinib hydrochloride combined with chemotherapy on the neovascularization capacity and mitogen-activated protein kinase(MEK)/extracellular signal-regulated kinase(ERK)pathway in patients with cervical cancer.Methods Sixty-eight cervical cancer patients admitted to our hospital from August 2020 to August 2022 were selected,and assigned into two groups using the method of random number table methods,with 34 in each.The control group was given routine chemotherapy,the experimental group added anlotinib based on the control group.The clinical efficacy,neovascularization capacity[vascular endothelial growth factor(VEGF),microvessel density(MVD)],and expression of MEK/ERK pathway related proteins were compared between the 2 groups.Results The experimental group reported a higher clinical efficacy rate as compared with the control[88.23%(30/34)vs.58.82%(20/34),χ2=7.555,P<0.05].A reduction in VEGF and MVD was observed in all patients after treatment,and the reduction was more notable in the experimental group than in the control[(63.98±5.14) ng·g-1 vs.(48.06±5.35) ng·g-1,(13.02±1.65)capillaries·mm-2 vs(6.68±1.62) capillaries·mm-2,t=12.512,15.987,all P<0.05].The expression of MEK1,MEK2 and ERK1/2 was down-regulated in the experimental group as compared with the control[(1.23±0.21) ng·mL-1 vs(2.06±0.19) ng·mL-1,(1.06±0.15) ng·mL-1 vs(2.28±0.14) ng·mL-1,(0.84±0.11) ng·mL-1 vs(1.48±0.12) ng·mL-1,t=17.089,34.670,22.924,all P<0.05].Conclusion Application of anlotinib hydrochloride combined with chemotherapy can effectively inhibit the neovascularization capacity and down-regulate the expression of MEK/ERK pathway related proteins in patients with cervical cancer.
Cervical cancerAnlotinibChemotherapyNeovascularization capacityMitogen-activated protein kinase/extracellular signal-regulated kinase pathway
NETL
NSTL
万方数据
